<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038996</url>
  </required_header>
  <id_info>
    <org_study_id>SNP_irAE</org_study_id>
    <nct_id>NCT04038996</nct_id>
  </id_info>
  <brief_title>The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors</brief_title>
  <official_title>A Single-Center, Prospective, Observational Trial to Analyze the Relationship Between Single Nucleotide Polymorphism rs2910164 and the Efficacy and Safety of Immune Checkpoint Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a&#xD;
      gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single nucleotide polymorphism (SNP) rs2910164 within the gene for microRNA-146a&#xD;
      (miR-146a) reduces miR-146a expression. Previous studies of the investigators demonstrated&#xD;
      that this SNP was associated with increased acute GvHD severity in patients undergoing&#xD;
      allogeneic hematopoietic stem cell transplantation. In this prospective, observational study&#xD;
      the investigators aim to analyze, whether SNP rs2910164 is associated with severity of&#xD;
      immune-related adverse events of immune checkpoint inhibitor therapy. Moreover, association&#xD;
      of rs2910164 with outcome parameters will be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of immune-related adverse events (irAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>according to CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Actual">179</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The rs2910164 genotype will be assessed using DNA isolated from peripheral blood samples and&#xD;
      Taqman realtime PCR assays.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with cancer undergoing immune checkpoint inhibitor therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  confirmed diagnosis of cancer&#xD;
&#xD;
          -  treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA4)&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  peripheral blood sample available&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  ability to understand the nature of the study and the study related procedures and to&#xD;
             comply with them&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg</affiliation>
  </overall_official>
  <reference>
    <citation>Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7269-74. doi: 10.1073/pnas.0802682105. Epub 2008 May 12.</citation>
    <PMID>18474871</PMID>
  </reference>
  <reference>
    <citation>Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.</citation>
    <PMID>28484267</PMID>
  </reference>
  <results_reference>
    <citation>Marschner D, Falk M, Javorniczky NR, Hanke-Müller K, Rawluk J, Schmitt-Graeff A, Simonetta F, Haring E, Dicks S, Ku M, Duquesne S, Aumann K, Rafei-Shamsabadi D, Meiss F, Marschner P, Boerries M, Negrin RS, Duyster J, Zeiser R, Köhler N. MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI Insight. 2020 Mar 26;5(6). pii: 132334. doi: 10.1172/jci.insight.132334.</citation>
    <PMID>32125286</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Head of Department of Tumorimunnology and Immunoregulation</investigator_title>
  </responsible_party>
  <keyword>immune checkpoint inhibitor</keyword>
  <keyword>single nucleotide polymorphism</keyword>
  <keyword>microRNA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

